Keywords
Advanced lung cancer
Vascular targeted therapy
Recent efficacy
Drug safety
Submitted : 2024-01-23
Accepted : 2024-02-07
Published : 2024-02-22
Abstract
Objective: To analyze the clinical efficacy, progression-free survival, and safety of anlotinib in the treatment of advanced lung cancer. Methods: A retrospective analysis was conducted using data from 60 patients with advanced lung cancer treated with anlotinib from May 2019 to May 2021. This analysis aimed to comprehensively evaluate the clinical efficacy, progression-free survival, and adverse reactions of anlotinib. Results: The median progression-free survival (PFS) for the 60 patients was 5.79 months, with an overall response rate (ORR) of 21% and a disease control rate (DCR) of 90%. In the first-line group, the median PFS was 6.20 months, ORR was 76.92%, and DCR was 84.61%. The second-line group showed a median PFS of 6.30 months, ORR of 28.57%, and DCR of 90.48%. In the third-line group, the median PFS was 5.34 months, ORR was 19.23%, and DCR was 92.30%. The single-agent group exhibited a median PFS of 5.09 months, ORR of 23.33%, and DCR of 76.67%. In the combination group, the median PFS was 6.53 months, ORR was 46.67%, and DCR was 100%. The combination group demonstrated a significantly higher medication effect than the single-drug group, and adverse drug reactions were mostly grade 1–2. Conclusion: Anlotinib exhibits a better disease control rate and survival benefit in the treatment of advanced lung cancer. The combination effect is superior to monotherapy, with relatively controllable adverse effects.
References
Xu J, Yu X, Ma H, et al., 2023, Death Trend of Lung Cancer in China from 2006 to 2020 Based on Age-Period-CohortModel. Cancer Research on Prevention and Treatment, 50(8): 788–793. https://doi.org/10.3971/j.issn.1000-8578.2023.22.1537
Zhu X, Jiang D, Shen J, et al., 2023, Incidence and Mortality of Lung Cancer in Countries with Different Human Development Index. Shanghai Journal of Preventive Medicine, 35(4): 305–313. https://doi.org/10.19428/j.cnki.sjpm.2023.22838
Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68(6): 394–424. https://doi.org/10.3322/caac.21492
Chen W, Zhang S, Zou X, 2010, Estimation and Projection of Lung Cancer Incidence and Mortality in China. Zhongguo Fei Ai Za Zhi, 13(5): 488–493. https://doi.org/10.3779/j.issn.1009-3419.2010.05.20
Strumberg D, Richly H, Hilger RA, et al., 2005, Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients with Advanced Refractory Solid Tumors. J Clin Oncol, 23(5): 965–972. https://doi.org/10.1200/JCO.2005.06.124
Yang S, Zhao Y, 2023, Evaluation of the Effect of Anlotinib Hydrochloride in the Treatment of Advanced Non-Small Cell Lung Cancer. China Medical Journal of Metallurgical Industry, 40(4): 449.
Ding Z, Men S, Zhang J, et al., 2023, Observation on the Effect of Anlotinib Combined with AP Chemotherapy Regimen for Advanced Non-Small Cell Lung Cancer. Clinical Medicine, 43(7): 110–112.
Duan Z, Chen Z, Shen X, 2023, Analysis of the Efficacy of Third-Line Treatment of Advanced Non-Small Cell Lung Cancer with Anlotinib and Its Prognostic Influencing Factors. Journal of Medical Forum, 44(19): 47–52 + 56.
Qiu Y, Huang P, Liu P, et al., 2023, Exploring the Clinical Efficacy and Safety of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer. China Practical Medicine, 18(19): 25–29.
Siegel RL, Miller KD, Fuchs HE, et al., 2021, Cancer Statistics, 2021. CA Cancer J Clin, 71(1): 7–33. https://doi.org/10.3322/caac.21654
Qin M-M, Ma D-B, Li X-L, et al., 2018, Rhamnetin Treatment Enhances the Sensitivity of Non Small Cell Lung Cancer Cells to Anlotinib, a Novel Molecular Targeted Agent. Science Technology and Engineering, 18(24): 213–219.
Zhang M, Gu J, Liu C, et al., 2021, Analysis of the Efficacy and Safety of Anlotinib in the First-Line Treatment of Elderly Patients with Extensive-Stage Small Cell Lung Cancer. Cancer Research and Clinic, 33(7): 541–543.
Zhou Z, Shi Q, Chen Q, et al., 2021, Effectivity Study of Anlotinib Hydrochloride in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer with Negative Driver Gene. Guide of Chinese Medicine, 19(34): 47–48 + 51.
Han B, Li K, Zhao Y, et al., 2018, Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302). Br J Cancer, 118(5): 654–661. https://doi.org/10.1038/bjc.2017.478
Han B, Li K, Wang Q, et al., 2018, Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients with Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol, 4(11): 1569–1575. https://doi.org/10.1001/jamaoncol.2018.3039